News | Proton Therapy | November 03, 2022

The MEVION S250-FIT would be the first and only proton therapy system that can be installed in an existing LINAC vault.

The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)

The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)


November 3, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). Stanford Health Care has been selected as the first site where the system will be developed and installed.

Proton therapy is a precise form of radiation therapy that reduces the amount of unnecessary radiation exposure to healthy tissue, which has the potential to decrease or eliminate the treatment side effects and lessen the risk of secondary malignancies.

Historically, the size, cost, and inherent complexity of proton technologies have limited the adoption of proton therapy. Mevion believes that the MEVION S250-FIT system has the potential to overcome the practical challenges of other technologies because the system is designed to be a more compact, affordable solution that can fit into an existing LINAC vault. Today, new proton therapy centers in the U.S. are almost exclusively compact single-room systems. Mevion’s compact system would continue to advance the design and accessibility of proton therapy. The MEVION S250-FIT system is currently in development and has not received regulatory clearance for clinical use.

“Mevion is dedicated to making proton therapy deployment similar to conventional radiation by simplifying room renovation requirements, enabling faster installation, and facilitating integration with other radiation therapy modalities,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “Through our arrangement with Stanford Health Care, Mevion is aiming to demonstrate that proton therapy can fit in an existing vault of a radiation oncology department and in turn become more accessible.”

For more information: www.mevion.com

*The MEVION S250-FIT Proton Therapy System has not received regulatory clearance.

 

Find more ASTRO22 content here


Related Content

News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 09, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
Subscribe Now